Clinical Trial

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a cancer-testis antigen (CTA) which is expressed in various tumors. In TCR-T therapy, researchers take the blood of a certain patient, select T cells and insert genes into the cell that expressing a kind of protein that targeting NY-ESO-1. The genetically engineered cells are called NY-ESO-1 TCR-T cells. Then the engineered cells are re-infused to the cancer patients to cure the disease or prolong life.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-25; most recent amendment 2025-07-11.
Trial Details
NCT Number NCT05881525
Lead Sponsor TCRCure Biopharma Ltd.
Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Advanced Solid Tumors
Enrollment 18 participants
Start Date 2023-06-01
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-16